Borje S. Andersson
Department of Stem Cell Transplantation and Cellular Therapy
The University of Texas M.D. Anderson Cancer Center
Houston
Texas 77030
USA
Name/email consistency: high
- Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Andersson, B.S., de Lima, M., Thall, P.F., Madden, T., Russell, J.A., Champlin, R.E. Curr. Opin. Oncol (2009)
- Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Andersson, B.S., de Lima, M., Thall, P.F., Wang, X., Couriel, D., Korbling, M., Roberson, S., Giralt, S., Pierre, B., Russell, J.A., Shpall, E.J., Jones, R.B., Champlin, R.E. Biol. Blood Marrow Transplant. (2008)
- Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Andersson, B.S., Kashyap, A., Gian, V., Wingard, J.R., Fernandez, H., Cagnoni, P.J., Jones, R.B., Tarantolo, S., Hu, W.W., Blume, K.G., Forman, S.J., Champlin, R.E. Biol. Blood Marrow Transplant. (2002)
- Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Andersson, B.S., Thall, P.F., Madden, T., Couriel, D., Wang, X., Tran, H.T., Anderlini, P., de Lima, M., Gajewski, J., Champlin, R.E. Biol. Blood Marrow Transplant. (2002)
- Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Andersson, B.S., Madden, T., Tran, H.T., Hu, W.W., Blume, K.G., Chow, D.S., Champlin, R.E., Vaughan, W.P. Biol. Blood Marrow Transplant. (2000)
